GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Development of Sapacitabine Therapy in Leukemias

$237,113
William K Plunkett · University Of Tx Md Anderson Can Ctr · P50 · FY2011 · CA

Identifying novel resistance mechanisms in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)

$237,023
John Sfakianos · Icahn School Of Medicine At Mount Sinai · R21 · FY2023 · CA

Targeting the Androgen Receptor to Sensitize Bladder Cancer to Immune Check Point Blockade.

$237,023
David Mulholland · Icahn School Of Medicine At Mount Sinai · R21 · FY2024 · CA

Development of Molecular Microbubble Probes and Ultrasound-Guidance in Immunotherapeutic Strategies

$236,985
Ahmed El Kaffas · Stanford University · R21 · FY2021 · EB

HDAC4 Viability: Unique Mechanisms and Function

$236,702
Gary D Kao · University Of Pennsylvania · R01 · FY2007 · CA

Molecular Imaging Reagents for Prostate Cancer Theranostics

$236,471
Zaver M Bhujwalla · Johns Hopkins University · P41 · FY2021 · EB

P3: Molecular Mechanisms Underlying Therapy Response to Radiation and Immune Checkpoint BlockadeýSUBAWARD

$236,408
David Sung-Wen Yu · Cleveland Clinic Lerner Com-Cwru · U54 · FY2022 · CA

Project 1: Combining PARP inhibition with radiation to sensitize HR proficient pancreatic cancers to immunotherapy

$236,326
Meredith A Morgan · University Of Michigan At Ann Arbor · P50 · FY2025 · CA

Developing GRB2-PROTACs for Treatment of Lung Cancer

$236,321
Haitao Mark Ji · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2023 · CA

Defining and targeting the immune-suppressive metabolic microenvironment of leptomeningeal melanoma metastases

$236,321
Inna Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2022 · CA

Prediction and Treatment for Cancer Immunotherapy Induced Myocarditis

$236,250
Hua Pan · Washington University · R21 · FY2022 · HL

MOLECULAR MECHANISMS OF MAMMALIAN CHECKPOINT PATHWAYS

$236,250
St. Jude Children'S Research Hospital · R01 · FY2004 · CA

Multifunctional Nanoprobe for Early Appraisal of Immunotherapeutic Efficacy

$236,250
Srikanth Singamaneni · Washington University · R21 · FY2021 · EB

ASPECTS OF UTERINE CELL CYCLE REGULATION IN IMPLANTATION

$236,250
University Of Kansas Medical Center · R01 · FY2001 · HD

MOLECULAR MECHANISMS OF MAMMALIAN CHECKPOINT PATHWAYS

$236,250
St. Jude Children'S Research Hospital · R01 · FY2003 · CA

Single-Cell Transcriptome & Effect of Immune Checkpoint Therapy on Kaposi Sarcoma

$236,250
Lee Ratner · Washington University · R21 · FY2022 · CA

MOLECULAR MECHANISMS OF MAMMALIAN CHECKPOINT PATHWAYS

$235,988
St. Jude Children'S Research Hospital · R01 · FY2002 · CA

Chemical platform to produce covalent biologics

$235,901
Alexander V Statsyuk · University Of Houston · R21 · FY2022 · GM

Immune cell states in endocrine immune related adverse events (IRAEs)

$235,895
Melissa G Lechner · University Of California Los Angeles · U19 · FY2025 · AI

RP-3: Elucidating Mechanisms of Sensitivity and Resistance to Checkpoint Blockade Therapy for Rational Multi-Drug Immunotherapy in Urothelial Cancers

$235,745
Jonathan Eric Rosenberg · Sloan-Kettering Inst Can Research · P50 · FY2024 · CA

P53 MEDIATED G2/M CHECKPOINT CONTROL

$235,675
Thomas Jefferson University · R01 · FY2000 · CA

Specificity of the Ubiquitin System in Lymphoid Malignancies

$235,667
Luca Busino · University Of Pennsylvania · R00 · FY2016 · CA

Novel mouse models using MADR-GESTALT technology to accelerate glioma research

$235,632
Linda M Liau · University Of California Los Angeles · P50 · FY2023 · CA

Endocrine tissue molecular pathways dysregulated by immune checkpoint inhibitors causing ICI-triggered adverse events

$235,620
Yaron Tomer · Albert Einstein College Of Medicine · R21 · FY2023 · CA

PI3K opposes p27 and G1 arrest by TGF-B in human cancer

$235,586
Joyce Marie Slingerland · University Of Miami School Of Medicine · R01 · FY2007 · CA